Zuranolone
Medication used for postpartum depression / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Zuranolone?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression.[5][6] It is taken by mouth.[5]
Quick Facts Clinical data, Pronunciation ...
Clinical data | |
---|---|
Pronunciation | /zʊˈrænəloʊn/ zuu-RAN-ə-lohn |
Trade names | Zurzuvae |
Other names | SAGE-217; S-812217; SGE-797; BIIB-125 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Neurosteroid; GABAA receptor positive allosteric modulator |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99.5%[2][unreliable medical source?] |
Metabolism | CYP3A4[2][unreliable medical source?] |
Elimination half-life | 16–23 hours[3][4] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.271.331 |
Chemical and physical data | |
Formula | C25H35N3O2 |
Molar mass | 409.574 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.[5][6] An orally active inhibitory pregnane neurosteroid, zuranolone acts as a positive allosteric modulator of the GABAA receptor.[7][8][9]
Zuranolone was approved for medical use in the United States for the treatment of postpartum depression in August 2023.[6] It was developed by Sage Therapeutics and Biogen.[10]